

August 2021

medical benefit specialty drug update **bulletin**

Specialty Drug Program Updates for UnitedHealthcare Commercial, Community Plan, and Medicare Advantage

Review the following table to determine changes to our specialty medical injectable drug programs.

UPDATES TO DRUG PROGRAM REQUIREMENTS AND DRUG POLICIES

Drug Name	Effective Date	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	UHC Value & Balance Exchange	Treatment Uses	Summary of Changes
Synagis® (palivizumab)	Jul. 1, 2021	X				Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in high-risk children.	Add notification/prior authorization requirement

As a reminder, Synagis® was added to notification/prior authorization for UHC Commercial business on July 1, 2021. These changes affect UnitedHealthcare Commercial plan members, including members of affiliate plans, such as UnitedHealthcare of the Mid-Atlantic, Neighborhood Health Partnership and UnitedHealthcare of the River Valley.

With the season opening earlier than normal in some parts of the country, we'd like to remind you each member is eligible to receive coverage for up to five doses during the Synagis season, based on the clinical coverage criteria set forth in the medical drug policy.